# A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Source: https://onco.cc/trials/nct06619509/  
OnCo record `nct06619509` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Brigimadlin in advanced solid tumours, run by Boehringer Ingelheim, active and no longer recruiting.

## Summary

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine is a phase 2 interventional study registered as NCT06619509 by Boehringer Ingelheim, with 90 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2030-12-30. Interventions recorded: Brigimadlin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06619509
- Phase: 2
- Setting: A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours
- Sponsor: Boehringer Ingelheim
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06619509: https://clinicaltrials.gov/study/NCT06619509

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct06619509.json